Sort
48,018 grants matching “immunotherapy”
Metabolic reprogramming of Tregs in tumor immunity
$410,606Hongbo Chi · St. Jude Children'S Research Hospital · R01 · FY2019 · CA
Mechanisms of Fas Ligand Control of Insulitis Initiation in Autoimmune Diabetes
$410,605Abdel Hamad · Johns Hopkins University · R56 · FY2012 · AI
HLA II PRESENTATION OF ANTIGENS FOR VACCINE
$410,571Rongfu Wang · University Of Tx Md Anderson Can Ctr · P50 · FY2008 · CA
The structural and functional basis of MET exon 14 activation and acquired drug resistance
$410,565Natalia Jura · University Of California, San Francisco · R01 · FY2021 · CA
Targeting mechanisms of immune evasion in chemotherapy-induced senescent cells
$410,550James Jackson · Tulane University Of Louisiana · R01 · FY2024 · CA
Regulation of host immunity to impact virus persistence
$410,491Bumsuk Hahm · University Of Missouri-Columbia · R01 · FY2023 · AI
Regulation of host immunity to impact virus persistence
$410,491Bumsuk Hahm · University Of Missouri-Columbia · R01 · FY2025 · AI
Regulation of host immunity to impact virus persistence
$410,491Bumsuk Hahm · University Of Missouri-Columbia · R01 · FY2024 · AI
Combinational Immunotherapy Targeting the Melanoma-Associated Vasculature
$410,490Walter J Storkus · University Of Pittsburgh At Pittsburgh · R01 · FY2014 · CA
Dust Mite, Cockroach and Cat Allergens: Asthma
$410,454University Of Virginia Charlottesville · R01 · FY2002 · AI
HIV-1 gp120 induced CTL chemorepulsion:dysregulation of migration & localization
$410,450Mark Coleman Poznansky · Massachusetts General Hospital · R01 · FY2009 · AI
HIV-1 gp120 induced CTL chemorepulsion:dysregulation of migration & localization
$410,450Mark Coleman Poznansky · Massachusetts General Hospital · R01 · FY2008 · AI
Using dietary glutamine supplementation for melanoma prevention and targeted therapy
$410,444Mei Kong · University Of California-Irvine · R01 · FY2023 · CA
EVALUATION OF PROTEIN BASED MEDICATIONS AGAINST COCAINE
$410,438University Of Michigan At Ann Arbor · R01 · FY2003 · DA
Project 4: Translation and preclinical studies of a personalized pancreas cancer vaccine
$410,431William E Gillanders · Washington University · P50 · FY2020 · CA
Tissue-Engineered Models of Lymphatic Drainage in Breast Cancer
$410,413Esak Lee · Cornell University · R01 · FY2023 · CA
Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma
$410,395Ingunn Margarete Stromnes · University Of Minnesota · R01 · FY2024 · CA
FUNCTIONAL ANALYSIS OF PATHOGENIC AND PROTECTIVE PEANUT ALLERGEN-SPECIFIC HUMAN ANTIBODIES
$410,371Scott Dexter Boyd · Stanford University · R01 · FY2022 · AI
FUNCTIONAL ANALYSIS OF PATHOGENIC AND PROTECTIVE PEANUT ALLERGEN-SPECIFIC HUMAN ANTIBODIES
$410,371Scott Dexter Boyd · Stanford University · R01 · FY2021 · AI
Preclinical development of WP1066, an effective inhibitor of STAT3 activation for
$410,341Raymond J Budde · Houston Pharmaceuticals, Inc. · R44 · FY2011 · AI
Immune Monitoring Core
$410,341Laszlo George Radvanyi · University Of Tx Md Anderson Can Ctr · P01 · FY2012 · CA
Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor
$410,323David John Tweardy · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Elicitation of α4β7-Competitive Antibodies in Rhesus Macaques by a Synthetic V2 Immunogen
$410,241Ronald S. Veazey · Tulane University Of Louisiana · N01 · FY2019 · AI
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors
$410,221Fumito Ito · Roswell Park Cancer Institute Corp · R01 · FY2021 · CA
Leadership, Planning and Evaluation
$410,180Steven D Leach · Dartmouth College · P30 · FY2025 · CA